( )
The logic follows: reduce inflammation, improve metabolism, lose weight
While Ozempic is a GLP-1 agonist, Mounjaro is classified as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, or dual GIP/GLP-1 agonist, meaning it targets an additional pathway to help control blood sugar (and as a side effect, help with weight loss)
Among these, the largest trial, REIMAGINE 2, will run for 68 weeks, including a 16-week dose escalation period followed by 52 weeks of maintenance, enrolling 2,700 T2D patients on metformin (MET), with or without SGLT-2 inhibitors
This can happen in people who have never had kidney problems before
(PubMed) Gibson GE, Hirsch JA, Fonzetti P, Jordan BD, Cirio RT, Elder J